Security Patches:
BD FACSLyric™ System

December 2022

Last updated: March 7, 2023

Original Publication: January 25, 2023

BD has identified a patch from Microsoft™ that has been identified as critical or security related for December 2022. This patch should NOT be installed on BD FACSLyric™ System workstations at this time. If the patch has been installed, it can be uninstalled to restore proper software operation. Please contact BD Technical Support for help on removing the patch if necessary.

Windows Automatic Updates should also be paused to prevent reinstallation of the patch when the workstation is reconnected to the network. Updates should be paused for the maximum timeframe in anticipation of a revised patch from Microsoft™.

Customers that maintain patches independent of BD automated delivery should ensure that the patch is NOT installed on their BD systems as the acting responsible entity in order to maintain proper operation of the system and software.

BEGIN UPDATE A: Feb 6, 2023

Microsoft has published an update on the security patch for XPS documents in .NET with a new mitigation recommendation (labeled **Alternate Workaround**). The mitigation involves adding an entry to the Registry to disable the enhanced security behavior of the December XPS security patch without uninstalling the Cumulative Update for .NET. This solution allows the Windows Update service to continue to identify and install other security updates as released by Microsoft™. BD has verified that this alternate mitigation addresses the patching issue without affecting proper operation of the BD FACSLyric™ System. Customers should avoid opening XPS documents from sources other than the BD FACSLyric™ System itself once the mitigation is in place.

Please refer to the Knowledge Base article KB5022083 on the Microsoft Support site for technical details and additional information regarding the security patch compatibility workaround:

https://support.microsoft.com/en-au/topic/kb5022083-change-in-how-wpf-based-applications-render-xps-documents-a4ae4fa4-bc58-4c37-acdd-5eebc4e34556

Note: The prior workaround provided in the article (labeled **Workaround**) was also tested by BD and found to be ineffective in resolving the issue for the BD FACSLyric™ System. This mitigation is therefore **not recommended**.

END UPDATE A: Feb 6, 2023

BEGIN UPDATE B: Mar 7, 2023

Microsoft has published an out-of-band update as a final resolution for the issue. The update standalone package can be manually installed or imported into various Microsoft endpoint management solutions. This update also allows the Windows Update service to continue to identify and install other security updates as released by Microsoft™. BD has verified that the out-of-band update resolves the patching issue without affecting proper operation of the BD FACSLyric™ System.

Microsoft™ out-of-band updates

Patch name	Description	Patch ID	Notes
2023-01 Update for .NET Framework 3.5 and 4.7.2 for Windows 10 Version 1809 (KB5023333)	Install this update to resolve issues in Windows. For a complete listing of the issues that are included in this update, see the associated Microsoft Knowledge Base article for more information. After you install this item, you may have to restart your computer.	KB5023333	Applicable on BD FACSLyric™ IVD and RUO Systems.

BD Biosciences, San Jose, CA, 95131, U.S.
877.232.8995

bd.com

BD

2023-01 Update for .NET Framework 4.8 for Windows 10 Version 22H2 (KB5023322)	Install this update to resolve issues in Windows. For a complete listing of the issues that are included in this update, see the associated Microsoft Knowledge Base article for more information. After you install this item, you may have to restart your compute	KB5023322	Applicable on BD FACSLyric™ IVD and RUO Systems.

Please refer to the Knowledge Base article KB5022083 on the Microsoft Support site for technical details and additional information regarding the out-of-band update and how to download and apply it to the operating system:

https://support.microsoft.com/en-au/topic/kb5022083-change-in-how-wpf-based-applications-render-xps-documents-a4ae4fa4-bc58-4c37-acdd-5eebc4e34556

Note: The resolution also recommends removing any of the earlier workarounds posted by Microsoft. If you have applied the Alternate Workaround described in Update A of this bulletin, it should be removed before applying the out-of-band update.

END Update B: Mar 7, 2023

Microsoft™ patches

Patch name	Description	Patch ID	Notes
2022-12 Cumulative Update for .NET Framework 3.5 and 4.7.2 for Windows 10, version 1809 and Windows Server 2019 (KB5020866)	A security issue has been identified in a Microsoft software product that could affect your system. You can help protect your system by installing this update from Microsoft. For a complete listing of the issues that are included in this update, see the associated Microsoft Knowledge Base article. After you install this update, you may have to restart your system.	KB5020866	Applicable on BD FACSLyric™ IVD and RUO Systems.
2022-12 Cumulative Update for .NET Framework 3.5 and 4.8 for Windows 10, version 20H2, Windows 10 Version 21H1, Windows 10 Version 21H2 and Windows 10 Version 22H2 (KB5020872)	A security issue has been identified in a Microsoft software product that could affect your system. You can help protect your system by installing this update from Microsoft. For a complete listing of the issues that are included in this update, see the associated Microsoft Knowledge Base article. After you install this update, you may have to restart your system.	KB5020872	Applicable on BD FACSLyric™ IVD and RUO Systems.

The BD FACSLyric™ Flow Cytometer is a Class 1 Laser Product.

In the U.S., the BD FACSLyric™ Flow Cytometer is for In Vitro Diagnostic Use with BD FACSuite™ Clinical Application for up to six colors.

In the U.S., the BD FACSLyric™ Flow Cytometer is for Research Use Only with BD FACSuite™ Application for up to 12 colors. Not for use in diagnostic or therapeutic procedures.

In the E.U., the BD FACSLyric™ Flow Cytometer with the BD FACSuite™ Clinical and BD FACSuite™ Applications is an in vitro diagnostic medical device bearing a CE mark.

BD Biosciences, San Jose, CA, 95131, U.S.
877.232.8995

bd.com

BD